Elevated Basal Levels of C-Reactive Protein Are Considered Risk
Factors for Diabetes, Hypertension, and Cardiovascular Disease
LifeVantage
Corporation (OTCBB: LFVN), has been granted a third patent for its
flagship product Protandim® from the United States
Patent and Trademark Office. Protandim® has been clinically proven in
earlier studies to slow the progressive rate of aging by reducing
oxidative stress and this new patent further documents Protandim's®
effect on antioxidant enzymes in vivo, describing anti-inflammatory
effects such as the lowering of C-reactive protein. C-reactive protein
is widely considered by doctors and researchers as an indicator of the
amount of inflammation present in the body. Elevated basal levels of
C-reactive protein are considered risk factors for diabetes,
hypertension, and cardiovascular disease. Thepatent,
"Methods for Enhancing Antioxidant Enzyme Activity and Reducing
C-Reactive Protein Levels," was issued on August 25, 2009.
Dr. Joe McCord, one of the foremost authorities on the body's
antioxidant defense system and the co-discoverer of the important
antioxidant enzyme superoxide dismutase or SOD, said, "This patent
further underscores the unique and powerful actions of Protandim®
as a tool against not only oxidative stress, but also inflammation.
Chronic, low-level inflammation is now known to be associated with many
of the major diseases we face as we age, including atherosclerosis,
diabetes, obesity, and neurodegenerative diseases."
David W. Brown, LifeVantage President and CEO commented, "The issuance
of a third patent for Protandim® builds upon our
previous two patents and further separates LifeVantage and Protandim®
from other dietary supplements. It is difficult to receive a
patent for a dietary supplement. Protandim® is
uniquely and solidly based upon sound and proven science and the
issuance of this third patent marks a historic day for LifeVantage, and
sets an unparalleled standard in the dietary supplement industry."
Abstract of U.S. Patent No. 7,579,026: "Methods for Enhancing
Antioxidant Enzyme Activity and Reducing C-Reactive Protein Levels":
An antioxidant-promoting composition that increases antioxidant defense
potential in a subject is disclosed comprising Bacopa monniera extract;
milk thistle extract, ashwagandha powder, green tea extract, Gotu kola
powder, Ginko biloba leaf extract; Aloe vera powder; turmeric extract;
and N-acetyl cysteine. The antioxidant-promoting composition of the
invention safely induces cellular antioxidant potential to achieve an
overall net decrease in oxidative stress without the undesirable
side-effects associated with the individual components of the
antioxidant-promoting composition. Also disclosed is a method for
reducing the undesirable side-effects of free radicals in a subject by
administering to a subject in need of such antioxidants an effective
amount of antioxidant-promoting composition of the invention.
About LifeVantage Corporation
LifeVantage Corporation is a publicly traded (OTCBB: LFVN),
science-based, nutraceutical company dedicated to helping people reach
their health and wellness goals.. Founded in 2003 and based in San
Diego, Calif., LifeVantage develops products, including Protandim®,
that deliver significant health benefits to consumers. For more
information, visit www.LifeVantage.com.
About Protandim®
Protandim® is a clinically proven supplement that provides
substantial benefits for healthy aging. This patented indirect
antioxidant therapy works in a very different way than conventional
foods such as red wine, oranges, blueberries or other popular
antioxidant supplements. Unlike those types of products that have proven
to be largely ineffective in reducing oxidative stress caused by free
radicals, Protandim® is an indirect antioxidant therapy,
which stimulates the body's production of its own powerful antioxidant
enzymes. Protandim® works at the cellular level, triggering
cells to naturally increase production of protective antioxidant enzymes
such as superoxide dismutase (SOD), catalase, and glutathione synthase.
A peer-reviewed human clinical study showed that after Protandim®
was taken for 30 consecutive days, important biochemical markers of
aging were decreased by an average of 40%. The study also reported that
these markers of aging were reduced in the subjects taking Protandim®
to the level of a typical 20-year-old. Protandim® is
currently the subject of approximately 20 scientific studies at leading
universities and research facilities. The nature and stages of the
studies vary, as some of the testing is at a preliminary stage, while
other studies using Protandim® are currently
in progress. For more information about Protandim®,
visit www.LifeVantage.com.
Forward Looking Statements
This document contains forward-looking statements made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act
of 1995. Words and expressions reflecting optimism, satisfaction or
disappointment with current prospects, as well as words such as
"believe," "hopes," "intends," "estimates," "expects," "projects,"
"plans," "anticipates" and variations thereof, identify forward-looking
statements, but their absence does not mean that a statement is not
forward-looking. Such forward-looking statements are not guarantees of
performance and the Company's actual results could differ materially
from those contained in such statements. These forward-looking
statements are based on the Company's current expectations and beliefs
concerning future events affecting the Company and involve known and
unknown risks and uncertainties that may cause the Company's actual
results or outcomes to be materially different from those anticipated
and discussed herein. These risks and uncertainties include, among
others, the potential failure or unintended negative consequences of the
implementation of our network marketing sales channel; our ability to
retain independent distributors or to attract new independent
distributors on an ongoing basis; the potential for third party and
governmental actions involving our network marketing sales channel; the
potential for product liability claims against the Company; the risk
that government regulators and regulations could adversely affect our
business; future laws or regulations may hinder or prohibit the
production or sale of our existing product and any future products;
unfavorable publicity could materially hurt our business; and the
Company's ability to protect our intellectual property rights and the
value of our product. These and other risk factors are discussed in
greater detail in the Company's Annual Report on Form 10-KSB and
Quarterly Report on Form 10-Q under the caption "Risk Factors," and in
other documents filed by the Company from time to time with the
Securities and Exchange Commission. The Company cautions investors not
to place undue reliance on the forward-looking statements contained in
this document. All forward-looking statements are based on information
currently available to the Company on the date hereof, and the Company
undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of this
document, except as required by law.
*These statements have not been evaluated by the Food and Drug
Administration. This product is not intended to diagnose, treat, cure or
prevent any disease.
LifeVantage Corporation
Investor Contact:
Ioana
C. Hone, 858-312-8000 Ext. 4
or
Media Contact:
For
LifeVantage Corporation
Jan Strode, 619-890-4040
or
Jean
Golden, 612-385-2324